All News - ALZFORUM
Nov 8, 2024 · TYPE OF NEWS. Research News (4502) Conference Coverage (1405) Community News (278) Interviews (33) Book Reviews (7) DISEASE. Alzheimer's Disease (3333) Amyotrophic Lateral Sclerosis (541) Parkinson's Disease (477) Frontotemporal Dementia (434) Triplet Repeat Diseases (153) Dementia with Lewy Bodies (116) Progressive Supranuclear Palsy (95 ...
ALZFORUM | NETWORKING FOR A CURE
5 days ago · At an airport hotel outside of Madrid, researchers hunkered down for the better part of a week to trade news about clinical trials for Alzheimer’s disease. The field is watching the rollout for lecanemab and donanemab with bated breath, tweaking administration, debating appropriate use, and hoping for no more deaths.
Aducanumab Approved to Treat Alzheimer’s Disease
07 Jun 2021. In a watershed moment for the field, the U.S. Food and Drug Administration today approved the first Alzheimer’s treatment that tackles the underlying disease pathology. Biogen and Eisai’s anti-amyloid antibody aducanumab, now called Aduhelm, removes amyloid plaque from the brain, but its ability to slow cognitive decline has ...
A New Era of Alzheimer’s Treatment - ALZFORUM
Print. 22 Jun 2021. The Food and Drug Administration’s decision to greenlight aducanumab (trade name Aduhelm) for Alzheimer’s disease has touched off an explosion of criticism and debate (see Part 1 of this series). Some researchers, however, consider the approval an overall positive development that the neurodegeneration field can build on ...
Revised Again: Alzheimer's Diagnostic Criteria Get Another …
Sep 16, 2022 · Tools. 17 Aug 2023. Diagnostic criteria for Alzheimer’s disease were revised only five years ago, but the field has learned a lot since then. At the Alzheimer’s Association International Conference, held last month in Amsterdam, Clifford Jack of the Mayo Clinic in Rochester, Minnesota, proposed updates to the current “ATN” system.
How Will Alzheimer’s Trials, Treatment Change in 2023 and Beyond?
Tools. 07 Oct 2022. When Eisai and Biogen announced positive top-line results for their anti-amyloid antibody lecanemab, the trial became the first successful, completed Phase 3 Alzheimer's drug study in the Western world in more than 20 years. If lecanemab earns traditional approval from the U.S. Food and Drug Administration based on these ...
Do Two APOE4 Alleles Always Mean Alzheimer's? - ALZFORUM
Tools. 10 May 2024. For 30 years, APOE4 has ranked as the strongest genetic risk factor for Alzheimer’s disease, with two copies boosting the odds up to 15-fold. Now, scientists make the case that people with two APOE4 alleles are not merely at risk, but are destined to develop AD. As reported in Nature Medicine on May 6, researchers led by ...
CSF Proteins Spot Alzheimer’s Mutation Carriers Decades Before …
Tools. 27 Sep 2024. Long before carriers of autosomal-dominant AD mutations notice the first hints of memory loss, changes in their brains are well underway at the protein level. In a study published September 26 in Cell, scientists led by Carlos Cruchaga at Washington University in St. Louis provide further support for this concept.
HIV Drug Safe in Alzheimer’s Pilot Trial, Nudged Biomarkers
Mar 12, 2024 · Scores on the Mini-Mental State Exam (MMSE) and Preclinical Alzheimer Cognitive Composite (PACC-5) trended worse after treatment. When the scientists removed scores from two people who had caught COVID-19 during the study, most of the difference between baseline and post-trial scores disappeared. …
Beyond Microglia—Alzheimer’s Gene PLCγ2 Acts on Synapses, Too.
09 May 2024. The Alzheimer’s risk gene phospholipase C-γ2 has been thought to act mainly in microglia. Now, in a May 1 preprint on bioRxiv, researchers led by Jean-Charles Lambert, Julie Dumont, and Julien Chapuis at Institut Pasteur de Lille, France, Mikko Hiltunen at the University of Eastern Finland, Kuopio, and Christophe Mulle at the …